Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.6.5.2 (
NQO1
)
6,196
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Self-protection in the mitomycin C (MC)-producing microorganism Streptomyces lavendulae includes
MRD
, a protein that binds MC in the presence of NADH and functions as a component of a unique drug binding-export system. Characterization of
MRD
revealed that it reductively transforms MC into 1,2-cis-1-hydroxy-2,7-diaminomitosene, a compound that is produced in the reductive MC activation cascade. However, the reductive reaction catalyzed by native
MRD
is slow, and both MC and the reduced product are bound to
MRD
for a relatively prolonged period. Gene shuffling experiments generated a mutant protein (
MRD
(E55G)) that conferred a 2-fold increase in MC resistance when expressed in Escherichia coli. Purified
MRD
(E55G) reduces MC twice as fast as native
MRD
, generating three compounds that are identical to those produced in the reductive activation of MC. Detailed amino acid sequence analysis revealed that the region around E55 in
MRD
strongly resembles the second active site of prokaryotic catalase-peroxidases. However, native
MRD
has an aspartic acid (D52) and a glutamic acid (E55) residue at the positions corresponding to the catalytic histidine and a nearby glycine residue in the catalase-peroxidases. Mutational analysis demonstrated that
MRD
(D52H) and
MRD
(D52H/E55G) conferred only marginal resistance to MC in E. coli. These findings suggest that
MRD
has descended from a previously unidentified
quinone reductase
, and mutations at the active site of
MRD
have greatly attenuated its catalytic activity while preserving substrate-binding capability. This presumed evolutionary process might have switched
MRD
from a potential drug-activating enzyme into the drug-binding component of the MC export system.
...
PMID:Characterization of a quinone reductase activity for the mitomycin C binding protein (MRD): Functional switching from a drug-activating enzyme to a drug-binding protein. 1115 72